23andMe, Inc. announced on 4 February it is becoming a publicly traded company through a merger with a special purpose acquisitions company (SPAC) backed by Virgin Group founder Sir Richard Branson in a deal that values the genetic-testing company at $3.5bn, including debt.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?